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Abstract Intragenic homozygous deletions in the Large
gene are associated with a severe neuromuscular phenotype
in the myodystrophy (myd) mouse. These mutations result
in a virtual lack of glycosylation of -dystroglycan. Com-
pound heterozygous LARGE mutations have been reported
in a single human patient, manifesting with mild congenital
muscular dystrophy (CMD) and severe mental retardation.
These mutations are likely to retain some residual LARGE
glycosyltransferase activity as indicated by residual -dys-
troglycan glycosylation in patient cells. We hypothesized
that more severe LARGE mutations are associated with a
more severe CMD phenotype in humans. Here we report a
63-kb intragenic LARGE deletion in a family with Walker-
Warburg syndrome (WWS), which is characterized by
CMD, and severe structural brain and eye malformations.
This Wnding demonstrates that LARGE gene mutations can
give rise to a wide clinical spectrum, similar as for other
genes that have a role in the post-translational modiWcation
of the -dystroglycan protein.
Introduction
Abnormal O-linked glycosylation of -dystroglycan is the
common pathogenic mechanism in a group of patients with
a clinical spectrum ranging from severe congenital muscular
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dystrophy (CMD), structural brain, and eye abnormalities
[Walker-Warburg syndrome (WWS), MIM 236670] to a
relative mild form of limb-girdle muscular dystrophy
(LGMD2I, MIM 607155) (van Reeuwijk et al. 2005a). In
muscle tissue, -dystroglycan acts as a bridge between the
extracellular matrix laminin and the actin cytoskeleton
through the transmembranal -dystroglycan. The interac-
tion of -dystroglycan with the extracellular matrix pro-
teins is mediated by its O-glycosylated moiety. Mature
-dystroglycan in brain binds to laminin and neurexin,
which is important for neuronal migration in the neocortex and
the integrity of the glia limitans (Barresi and Campbell 2006).
Mutations that result in hypoglycosylation of -dystro-
glycan have been identiWed in known and putative glyco-
syltransferase genes: FCMD, FKRP, LARGE, POMGnT1,
POMT1, and POMT2 (Freeze 2006). Four of these genes,
FCMD, FKRP, POMT1, and POMT2, have been implicated
in WWS. These genes explain approximately one-third of
the WWS patients in our cohort. Interestingly, diVerent
mutations in these genes are known to cause phenotypic
variability ranging from WWS to limb-girdle muscular dys-
trophy. Thus, it appears that mutations in genes that aVect
the glycosylation of -dystroglycan can give rise to a num-
ber of related disorders, thereby blurring the boundaries
between these clinically deWned ‘dystroglycanopathies’
(Freeze  2006; Mercuri et al. 2006; van Reeuwijk et al.
2006; van Reeuwijk et al. 2005a). Here, we have investi-
gated whether allelic variability does also occur for the
LARGE gene.
The LARGE protein is a putative glycosyltransferase,
required for addition of as yet unknown glycans onto the
-dystroglycan protein. Interestingly, overexpression of
LARGE can by-pass the glycosylation defects in cells from
patients with WWS or muscle-eye–brain disease (MEB,
MIM 253280) (Barresi et al. 2004). Mutations in LARGE
have been identiWed in a patient with relatively mild CMD
and severe mental retardation (MDC1D: MIM 608840).
This patient is compound heterozygous for p.E509K and
p.C667fs. These mutations do not seem to abolish the activ-
ity of the LARGE protein completely, as Western blot anal-
ysis of skeletal muscle from this patient indicates residual
functional glycosylation and laminin binding activity for
-dystroglycan (Longman et al. 2003). Interestingly, myd
mice that carry a spontaneous deletion in Large (Largemyd),
resemble the more severe clinical Fukuyama congenital
muscular dystrophy (FCMD, MIM 253800), and MEB
(Grewal et al. 2001; Longman et al. 2003; Michele et al.
2002).
Based on linkage studies we expect that there are multi-
ple other genes that give rise to a WWS phenotype when
mutated (van Reeuwijk et al. 2005b, and unpublished data).
Here we report a homozygous 63-kb intragenic deletion in
LARGE, in a patient who had familial classical WWS char-




Patient 1 is a Saudi female and was delivered normally at
term. Parents were second-degree cousins. Mother was
gravida 5 para 4 with uneventful pregnancy, no polyhy-
dramnios, or reduced fetal movements. Apgar scores were
5 and 8 at 1 and 5 min, respectively. Birth weight 2,880 g
(25th centile), length 50 cm (50th centile), head circumfer-
ence 37 cm (>90th centile). Physical examination (Fig. 1a)
showed no dysmorphic features, severe generalized hypoto-
nia with very little spontaneous movements of the limbs
and valgus deformity of the feet. She had poor respiratory
eVort. Anterior fontanel was wide with separated sutures,
Fig. 1 Phenotype and brain CT 
scans of patient 1 (a–c) and pa-
tient 2 (d–f). Patient 1 showed 
no dysmorphic features, severe 
generalized hypotonia with very 
little spontaneous movements of 
the limbs, and valgus deformity 
of the feet (a). Brain CT of pa-
tient 1 (b, c), and patient 2 (e, f) 
show absence of the inferior cer-
ebellar vermis, a hypoplastic 
cerebellum, and marked dilata-
tion of the lateral ventricles. Pa-
tient 2 also shows severe 
hydrocephalus with wide fonta-
nel and separated sutures and 
cysts (d–f)Hum Genet (2007) 121:685–690 687
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deep tendon reXexes were absent, and sensations were
intact. Ophthalmic examination revealed dense bilateral
congenital cataract in the left eye and mild lens opacity
with pigmentary degeneration of the retina and optic atro-
phy in the right eye. She was discharged from the Neonatal
Intensive Care Unit (NICU) at the age of 3 months. At the
age of 4 months her weight was on the 25th centile, length
10th centile and head circumference above 95th centile.
She was developmentally delayed and blind. She died at the
age of 6 months.
Laboratory investigations showed remarkably high-crea-
tine kinase (CK) of 28,600 U/l (N 24–170) on the third day of
life and 1,086 U/l at the age of 1 month. Liver function tests
(LFT), metabolic screen, TORCH panel for congenital infec-
tions were all normal. Chromosome analysis was normal
female karyotype. Brain CT (Fig. 1b, c) showed marked dila-
tation of the lateral ventricles with moderate dilatation of the
third ventricle, there was a striking decrease in attenuation
surrounding the dilated ventricles, the inferior cerebellar ver-
mis was absent, and the cerebellum was hypoplastic. EEG
showed frequent right tempro-occipital burst of sharp and
slow activity. Brain auditory evoked responses (BAER)
using monoaural click stimulation was normal. Muscle
biopsy showed features of dystrophy. A diagnosis of WWS
was made based on the CNS, eye, and muscle involvements.
No DNA or tissue sample was available for this study.
Patient 2 is the younger sibling of patient 1. Antenatal
ultrasound showed hydrocephalus and he was delivered by
emergency cesarean section. Apgar scores were 6 and 9 at 1
and 5 min, respectively. Physical examination (Fig. 1d)
showed severe hydrocephalus with wide fontanel and sepa-
rated sutures, and head circumference was 46 cm, above the
97th centile. He had generalized hypotonia, absent deep
tendon reXexes but no dysmorphic features. Ophthalmic
examination showed bilateral leukocornia, retinal dyspla-
sia, and posterior synechia. Brain CT (Fig. 1e, f) revealed
severe hydrocephalus with Dandy-Walker malformation
and minimal brain tissue, absent inferior cerebellar vermis
and hypoplastic cerebellum. CK was elevated at 18,000 U/l
(N 24–195). Lactate dehydrogenase was high at 1,690 U/l
(N 230–460). Liver enzymes were mildly elevated, alanine
aminotransferase (ALT) 53 U/l (N 10–50), and aspartate
aminotransferase (AST) 142 U/l (N 10–45 U/l). Tandem
mass spectrometry (MS) for metabolic screen was unre-
markable; TORCH for congenital infections was negative.
Chromosome analysis showed normal male karyotype.
Muscle biopsy was done at the age of 11 days and revealed
dystrophic features in the form of myoWber necrosis, baso-
philic  Wbers and interstitial endomysial, and perimysial
Wbrosis. There was no speciWc Wber type atrophy or group-
ing. A limited number of immunostains were done and
included dystrophin and -sarcoglycan. Both immunostains
were normally positive.
A ventriculoperitoneal shunt was inserted. He was
weaned oV the ventilatory support and died at the age of
2 months. A diagnosis of WWS was made.
Nine other siblings were born healthy and DNA was
obtained from seven, as well as the parents. A pedigree of
the family is given in Fig. 2.
Linkage analysis and mutation analysis
DNA was extracted from blood lymphocytes using stan-
dard procedures. Linkage to the LARGE locus was assessed
by genotyping two microsatellite markers Xanking the gene
(D22S281 and D22S529) and two intragenic markers
(D22S1162 and D22S1172).
Primer3 (http://www.frodo.wi.mit.edu) was used to
design speciWc primers (supplementary Table 1) for PCR
ampliWcation and direct sequencing of the 14 coding exons
(including intron–exon boundaries) of LARGE
(NM_004737.3).
Copy number detection
Copy number detection of the 16 LARGE exons was per-
formed by Multiplex AmpliWable Probe Hybridization
(MAPH). A series of probes for the 16 LARGE exons were
generated by PCR and cloned into pZERO (Invitrogen,
Carlsbad, CA, USA). MAPH was carried out and probe
ratios analyzed essentially as previously described (Armour
et al. 2000; Hollox et al. 2002).
Fig. 2 Family pedigree. Females are represented by circles, males by
squares. Open symbols represent the unaVected family members, the
solid black symbols the WWS aVected siblings688 Hum Genet (2007) 121:685–690
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Multiplex Ligation-dependent Probe AmpliWcation
(MLPA) was used to further restrict the deletion break-
points. MLPA probes were designed within exons 8–11 and
intron 8 and 10 of the LARGE gene (supplementary Table
2). A protocol for designing these probes and hybridization,
ligation, and ampliWcation of these probes is provided by
MRC-Holland (http://www.mlpa.com). Product separation
was performed using capillary electrophoresis on an ABI
3730 or 3100 sequencer (Applied Biosystems, Foster City,
CA). For quantitative analysis, trace data were retrieved
using Genemapper software following the manufacturer’s
protocol (Applied Biosystems).
Long-range PCR method and sequence analysis 
of breakpoints
The breakpoint-spanning region was ampliWed by long-
range PCR ampliWcation with speciWc primers (supplemen-
tary Table 3) and LA TaqTM (TaKaRa Bio Inc., Shiga,
Japan) using PCR conditions recommended by the manu-
facturer. We then used diVerent combinations of primers to
further restrict the breakpoint-spanning region and identi-
Wed the breakpoint by direct sequencing.
Results
Linkage to the LARGE locus and mutation analysis
We hypothesized that severe LARGE mutations give rise to
WWS. To assess this hypothesis we selected intragenic and
LARGE Xanking genetic markers to test for homozygosity
in 30 WWS patients from consanguineous parents. Seven
patients from six unrelated families showed homozygosity
for at least two intragenic markers (D22S1162 and
D22S1172) and one marker (D22S281 or D22S529) in
close proximity of LARGE.
We performed mutation analysis for all 14 coding exons
including intron–exon boundaries by direct sequence analy-
sis. No mutations were found. However, diYculties during
the PCR ampliWcation of some of the exons suggested a
possible deletion of these exons in one of the families. Two
aVected siblings in this family manifest typical WWS fea-
tures as described in the patients and methods section.
IdentiWcation of a submicroscopic deletion by copy number 
detection
Using MAPH we screened all 16 exons for copy number
changes. Exon 9 and 10 showed copy number changes in
one family, indicative for a deletion of these exons in
patient 2 (homozygous) and in the parents (hemizygous).
This result was conWrmed by MLPA analysis of probes spe-
ciWc to these exons and surrounding intronic sequences,
which also further deWned the size of the deletion to 61.1–
66.6 kb (Fig. 3).
Analysis of breakpoints
By long-range PCR ampliWcation we obtained a deletion-
spanning fragment of »3.5 kb from patient 2. Sequence
analysis of this fragment revealed the 5 and 3 breakpoints,
and a deletion size of 63.1 kb (Fig. 4). This genomic dele-
tion predicts a 239 bp deletion in the transcript resulting in
a shift of the open reading frame within the Wrst predicted
catalytic domain, coding for 29 alternative codons followed
by a premature stop codon, which most likely results in non-
sense-mediated decay of the transcript. Unfortunately no
cell-line or tissue sample was available to test this hypothe-
sis. Only the aVected individual was homozygous for the
deletion, the parents and Wve of the seven analyzed
unaVected sibs were heterozygous carriers of the deletion.
No signiWcant match between the 5 and 3 junction
sequences is present, therefore the LARGE deletion is likely
the result of non-homologous end-joining as reported also
for the Large deletion in myd mice (Browning et al. 2005).
Discussion
We previously reported mutations in POMT1,  POMT2,
FCMD, and FKRP in approximately one-third of the WWS
patients in our cohort (van Reeuwijk et al. 2005b). Here we
report a homozygous 63-kb intragenic deletion in LARGE in
a patient with WWS. The clinical features of the patients in
Fig. 3 MLPA analysis, showing a deletion of two exonic probes (EX9
and EX10) and two Xanking intronic probes (IN8-2 and IN10) in the
patient (diamonds), and in the unaVected carriers (black circles, trian-
gles, and squares). No intronic probes were tested for the patient due
to limited availability of DNA. Open circles, triangles, and squares de-
pict control individualsHum Genet (2007) 121:685–690 689
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this family do not diverge from the typical manifestations of
other WWS patients. Hence, none of the Wve WWS genes
that are known to date are associated with discriminating
clinical features. The deletion described in this report is
likely a loss of function mutation due to a predicted frame-
shift of the open reading frame within the Wrst predicted cata-
lytic domain. Mice carrying a similar disruptive defect in the
Large gene display a severe muscle, eye, and brain pheno-
type, and have a shortened life span. With regard to the brain
defects, these mice have severe neuronal migration defects
resulting in a lissencephalic phenotype (Holzfeind et al.
2002; Lee et al. 2005; Mathews et al. 1995; Michele et al.
2002). The only previously known human LARGE mutations
(p.E509K and p.C667fs) were identiWed in a patient with
CMD, subtle structural brain abnormalities and severe men-
tal retardation (MDC1D). The less severe clinical phenotype
of this patient could be explained by residual activity of the
LARGE protein. By an overlay assay, the authors demon-
strated that residual -dystroglycan present in a skeletal mus-
cle biopsy in the patient retained laminin-binding, whereas
this binding is lost in the myd mice (Holzfeind et al. 2002;
Longman et al. 2003; Michele et al. 2002).
The existence of phenotypic variability for diVerent
mutations is also reported for other WWS genes. Mutations
in the POMT1/2 genes were initially identiWed in WWS
(Beltrán-Valero de Bernabé et al. 2002; van Reeuwijk et al.
2005b), but subsequently also in milder conditions includ-
ing limb-girdle muscular dystrophy subtype 2K
(LGMD2K, MIM 609308) (Balci et al. 2005; Mercuri et al.
2006; van Reeuwijk et al. 2006). Conversely, FKRP muta-
tions are a common cause of LGMD, denoted subtype
LGMD2I, but rare mutations are also found in severe con-
ditions such as MEB and WWS, two similar disorders with
CMD and severe brain and eye malformations (van Ree-
uwijk et al. 2005a). A common hypomorphic mutation in
the FCMD gene causes FCMD in the Japanese population
(Kobayashi et al. 1998). However, loss-of-function FCMD
mutations are found in more severe conditions, including
WWS (Beltrán-Valero de Bernabé et al. 2003). Finally,
diVerent mutations in POMGnT1 cause phenotypic vari-
ability within the MEB disease spectrum (Taniguchi et al.
2003; Yoshida et al. 2001).
LARGE is localized to the Golgi apparatus but the exact
function of LARGE is unknown (Brockington et al. 2005;
Grewal et al. 2005). It contains two putative catalytic
domains, one related to a bacterial glycosyltransferase, and
one related to a human glycosyltransferase (Grewal et al.
2001). In addition, LARGE interacts with the N-terminal
domain of -dystroglycan, which is essential for normal
glycosylation of this protein (Kanagawa et al. 2004).
Another remarkable Wnding is the therapeutic potential of
LARGE, demonstrated by the recovery of dystroglycan
processing and functioning in WWS/MEB Wbroblasts by
overexpression of the LARGE gene (Barresi et al. 2004).
Our  Wnding demonstrates the existence of phenotypic
variability, especially with regard to the brain, caused by
diVerent mutations in LARGE. We identiWed a mutation in
this gene in 1 of 30 families, indicating that this gene is
causal for only a small percentage of WWS patients. How-
ever, two spontaneous mouse mutants for Large, both due
to intragenic deletions, have been reported in addition to
the WWS patient described here (Grewal et al. 2001; Lee
et al. 2005). The genomic size of LARGE may predispose
this gene for genomic deletions. To exclude LARGE from
genetic involvement in LGMD, or CMD with or without
brain involvement it will be important to examine patients
for genomic deletions in this gene.
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